Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Physiomics ( (GB:PYC) ) has issued an announcement.
Physiomics plc announced the resignation of Peter Sargent as CEO, effective May 2026, with Dr. Jim Millen stepping in as Executive Chairman to ensure continuity. The company remains on track with its revenue expectations and continues to progress in its growth initiatives, including a new biometrics service line and advancements in personalized medicine dosing software.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biometrics, supporting the development of new therapeutics and personalized medicine solutions. The company combines expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in streamlining their drug development processes. Physiomics uses cutting-edge computational tools and proprietary Virtual Tumour technology to inform the development of over 100 commercial projects, working with clients such as Merck KGaA, Astellas, and Bicycle Therapeutics.
Average Trading Volume: 2,690,859
Technical Sentiment Signal: Sell
Current Market Cap: £1.14M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.